Search the Newsreel

Is Stoke Therapeutics' (STOK) New Shelf Filing Reframing Its Path Through Mounting Operating Losses?

Stoke Therapeutics (STOK) reported a significant net loss of US$61.62 million in Q2 2026 and US$111.62 million for the first half of 2026, alongside a drop in sales. The company also filed a US$57.72 million shelf registration for 2,000,000 common shares, signaling potential future …

Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Stoke Therapeutics announced that CEO Ian F. Smith will present at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, at 3:00 p.m. ET. The biotechnology company focuses on RNA medicine to restore protein expression, with its lead investigational medicine, zorevunersen, in …

Has Stoke Therapeutics (STOK) Become A Bargain As Losses Widen And ESOP Shares Hit The Shelf?

Stoke Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:STOK) 2026-08-07

Stoke Therapeutics, Inc. (NASDAQ:STOK) released its Q2 2026 earnings call presentation on August 7, 2026. The company reported an EPS of -$0.93, missing estimates by $0.15, and revenue of $9.33M, which beat expectations by $4.24M despite a 32.51% year-over-year decrease. The presentation provides detailed …

Stoke Therapeutics Inc (STOK) Stock News Today

FMR LLC discloses 8.5% Stoke Therapeutics (STOK) ownership in Schedule 13G/A

FMR LLC has filed an amended Schedule 13G/A, reporting a passive ownership stake of 8.5% in Stoke Therapeutics (STOK) common stock. This represents 5,313,100 shares, with FMR LLC holding sole voting power over 5,312,516 shares and sole dispositive power over all 5,313,100 shares. Abigail …

Analysts Have Made A Financial Statement On Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Second-Quarter Report

Stoke Therapeutics (NASDAQ:STOK) saw its shares rise 8.3% after its second-quarter report, with revenues of US$9.3m exceeding expectations, though losses also increased. Analysts have since raised revenue estimates for 2026 to US$30.2m but also increased loss per share forecasts to US$3.71, indicating higher costs …

Stoke Therapeutics Inc (STOK) Earnings Forecast: Future EPS & Revenue Growth Estimates

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

Stoke Therapeutics announced that its CEO, Ian F. Smith, and Chief Patient Officer, Jason Hoitt, will present at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The biotechnology company focuses on RNA medicine to restore protein expression, with its lead investigational …

Stoke Therapeutics (NASDAQ:STOK) Insider Sells $208,391.04 in Stock

Stoke Therapeutics insider Barry Ticho sold 7,176 shares of the company's stock for $208,391.04, reducing his holdings by 26%. This sale was made under a Rule 10b5-1 trading plan. The company recently reported mixed quarterly results, with revenue exceeding estimates but a wider-than-expected loss, …

Stoke Therapeutics (STOK) CMO sells 7,176 shares under 10b5-1 plan

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, sold 7,176 shares of common stock on August 3, 2026, under a Rule 10b5-1 trading plan adopted on November 19, 2025. The sales occurred in two transactions at weighted-average prices of $28.9501 and $29.4539 per share. Following …

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics reported its Q2 2026 financial results, highlighting significant progress in its clinical programs. The company completed enrollment for the Phase 3 EMPEROR study of zorevunersen for Dravet syndrome, with data expected in Q3 2027, and plans to initiate a rolling U.S. NDA …

Stoke: 'Buy' Zorevunersen NDA SCN1A DS And STK-002 Advancement (NASDAQ:STOK)

Stoke Therapeutics (STOK) maintains a "Buy" rating due to significant progress in its clinical programs. Key milestones include an expected FDA meeting in H2 2026 and a rolling NDA submission in Q1 2027 for zorevunersen in SCN1A Dravet Syndrome, with Phase 3 EMPEROR data …

Stoke Therapeutics, Inc. Stock 12‑Month Price Target Cut to $45.64, Implies 54% Upside

Analysts have lowered the average 12-month price target for Stoke Therapeutics, Inc. (STOK) stock to $45.64 from $46.87, representing a potential 54% upside based on its August 3 closing price. Despite the cut, the consensus rating from 13 analysts remains a "Buy," with forecasts …

Stoke Therapeutics (STOK) Stock Climbs As Cash Burn Meets Dravet Momentum

Stoke Therapeutics' stock rose 7% despite a widened net loss in Q2 2026, driven by positive momentum in its Phase III Dravet syndrome program. The company's cash position of US$420 million is expected to fund operations into the planned launch window, addressing investor concerns …

Wedbush Adjusts Price Target on Stoke Therapeutics to $40 From $38, Maintains Outperform Rating

Wedbush has increased its price target for Stoke Therapeutics (NASDAQ: STOK) to $40 from $38, while reiterating an Outperform rating on the stock. This adjustment follows recent company news, including the Q2 2026 earnings call and updates on their Phase 3 study for Dravet …

Stoke Therapeutics, Inc. Q2 2026: Revenue $9.3M, EPS $(0.93) — 10-Q Summary

Stoke Therapeutics, Inc. reported its Q2 2026 results, showing a decrease in revenue to $9.3M from $13.8M in Q2 2025, and a widened net loss of $(61.6M) with a diluted EPS of $(0.93). The company highlighted clinical progress for zorevunersen with Phase 3 trial …

Stoke outlines rolling NDA in Q1 2027 as $420M cash supports potential U.S. launch by early 2028

Earnings Call Insights: Stoke Therapeutics (STOK) Q2 2026 MANAGEMENT VIEW * "Starting with our Phase III EMPEROR study, the recent completion of enrollment of 162 patients in just 10 months speaks to the awareness and enthusiasm of zorevunersen" (CEO & Director Ian Smith). "We …

How Stoke Therapeutics Inc. (STOK) Affects Rotational Strategy Timing

This article analyzes Stoke Therapeutics Inc. (STOK) using AI models to provide trading strategies for different risk profiles and holding periods. It highlights divergent sentiment, support/resistance levels, and a favorable risk-reward setup for the stock. The analysis includes position trading, momentum breakout, and risk …

Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Rating of "Moderate Buy" by Analysts

Stoke Therapeutics (NASDAQ:STOK) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $43.00, despite recently missing earnings per share estimates while exceeding revenue forecasts. Insider sales by two executives under pre-arranged plans have been noted, though insiders …

Stoke Therapeutics (NASDAQ:STOK) Issues Quarterly Earnings Results, Misses Estimates By $0.13 EPS

Stoke Therapeutics reported a quarterly loss of $0.93 per share, missing analyst estimates by $0.13, despite revenue of $9.32 million exceeding expectations. The company remains unprofitable, but its shares rose by $0.70 to $29.56 following the announcement. Analysts maintain a "Moderate Buy" consensus with …

Earnings Flash (STOK) Stoke Therapeutics, Inc. Reports Q2 Revenue $9.3M, vs. FactSet Est of $4.9M

Stoke Therapeutics (NASDAQ: STOK) swings to H1 2026 loss as revenue falls

Stoke Therapeutics reported a significant financial downturn in H1 2026, swinging to a net loss of $111.6 million compared to a net income of $89.4 million in H1 2025, primarily due to a sharp decline in revenue from $172.4 million to $15.6 million. This …

Stoke's Dravet trial enrolls 162; data readout anticipated Q3 2027

Stoke Therapeutics announced the completion of enrollment for its Phase 3 EMPEROR study of zorevunersen in Dravet syndrome, with 162 patients enrolled and a data readout expected in Q3 2027. The company is preparing for a rolling U.S. NDA submission to begin in Q1 …

Earnings call transcript: Stoke Therapeutics posts Q2 2026 revenue beat as Dravet drug advances

Stoke Therapeutics reported a wider-than-expected Q2 2026 loss but significantly beat revenue forecasts, driven by the advancement of its Dravet syndrome drug, zorevunersen, towards a potential U.S. launch in early 2028. The company's Phase III EMPEROR study has exceeded enrollment targets with no patient …

Stoke Therapeutics faces earnings test as Dravet drug awaits data

Stoke Therapeutics earnings missed by $0.16, revenue topped estimates

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics, Inc. $STOK Shares Acquired by Janus Henderson Group PLC

Janus Henderson Group PLC increased its stake in Stoke Therapeutics (NASDAQ:STOK) by 11.2% in the first quarter, now owning over 1.6 million shares valued at approximately $52.5 million. Despite a quarterly loss, analyst sentiment remains positive with a "Moderate Buy" consensus rating and an …

OMERS ADMINISTRATION Corp Invests $1.35 Million in Stoke Therapeutics, Inc. $STOK

OMERS ADMINISTRATION Corp initiated a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK) during the first quarter, purchasing 41,500 shares valued at approximately $1.35 million. Other institutional investors like Baillie Gifford & Co., Hussman Strategic Advisors Inc., and Candriam S.C.A. also hold significant stakes, with …

Stoke Therapeutics Inc (STOK) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Stoke Therapeutics Inc (STOK), indicating its current valuation score is 8.30, ranking 147 out of 384 in the Biotechnology & Medical Research industry. The company's P/E ratio is -10.31, significantly below its recent high and above its …

Stoke Therapeutics (STOK) Expected to Release Earnings on Monday

Stoke Therapeutics (NASDAQ:STOK) is anticipated to release its Q2 2026 earnings before market open on Monday, August 3rd. Analysts project a loss of $0.82 per share and $4.89 million in revenue. The company's stock, currently trading around $29.20, holds a "Moderate Buy" consensus rating …

Stoke Therapeutics, Inc. $STOK Position Increased by Redmile Group LLC

Redmile Group LLC increased its stake in Stoke Therapeutics (STOK) by 3.2% in the first quarter, now owning 4.16 million shares valued at $135.6 million. Other institutional investors like Janus Henderson and State Street also boosted their positions, while company insiders sold shares. Despite …